SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining significant community traction as supporters rally behind its long-term vision of becoming a global cryptocurrency for cannabis culture. Investors are actively discussing the project's consistent development and cultural appeal ahead of key seasonal events, viewing it as a grassroots alternative to traditional industry stocks.

The Shrimp Army

The community is actively trading SHRIMPS as part of a broader trend of animal-themed memecoins, sparking intense debate over whether it represents a legitimate high-growth opportunity or a short-lived pump-and-dump scheme. Market participants are closely watching price volatility and momentum, with many warning of the high risks associated with these rapid boom-and-bust cycles.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as investors position for the highly anticipated SpaceX IPO, with community members noting the fund's high concentration in SpaceX and Anthropic as a strategic play. Discussions are fueled by speculative reports of an imminent IPO filing and comparisons to other venture-focused funds, with participants debating the fund's premium to net asset value and the long-term potential of its private tech holdings.

Chess Grandmaster Hans Nieman was accused of cheating during a tournament by wearing a vibrating butt plug which sent morse code for which move he should make. In response dev Ron Sijim created the Buttfish Github.   Buttfish is a github repository which explains how a vibrating butt plug could transmit morse code for chess. In this github he literally says this project is a "meme" so why not make him a memecoin.   He also has a Eth wallet listed for donations, so clearly he is crypto native  Send Buttfish Coin

Buttfish Coin

Investors are actively debating the high volatility and liquidity constraints of this sea-themed cryptocurrency while drawing comparisons to other niche speculative assets in the sector.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is capturing significant community attention as a potential DePIN and Web3 breakout candidate, fueled by its low market cap and the promise of its secure, decentralized nMobile communications platform. Traders are actively debating whether the asset is currently experiencing manipulative price suppression or coiling for a major move as they compare its utility and scarcity against other high-growth altcoins.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is driving significant community discourse as the company expands its aggressive Bitcoin acquisition strategy through additional capital raises, sparking intense debate between bulls who view the firm as a premier leveraged proxy for institutional adoption and bears who express concerns over dilution and price sensitivity. The community remains hyper-focused on the company's complex premium to its net asset value and the tactical interplay between institutional buying patterns and high-leverage short positions.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with broader software sector pessimism and concerns surrounding the company's heavy capital expenditures on AI initiatives. The community is actively debating whether this decline represents a long-term value opportunity or a systemic shift in the stock's performance, with many noting a disconnect between the company's solid financial fundamentals and its ongoing downward price action.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh significant international expansion, including new German healthcare partnerships and the acquisition of BrewDog, against skepticism regarding the company's long-term financial health and potential for further share dilution. The community remains heavily divided between bulls anticipating an imminent short squeeze driven by pending U.S. cannabis rescheduling (Schedule III) and bears citing a history of aggressive equity dilution and struggling alcohol revenue as reasons for further potential downside.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is seeing intense volatility as investors debate the impact of Middle East tensions, with some market participants pointing to a potential inflection point at the 245 level following a prolonged consolidation range. The community is actively split, with some traders citing signs of a parabolic squeeze in small caps while others warn of the risks posed by shifting credit cycles and geopolitical headlines.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The GDX is currently seeing heightened volatility and mixed sentiment as investors weigh persistent inflationary pressures against the impact of central bank liquidity management and geopolitical uncertainty. Market participants are actively debating whether current price levels represent a prime accumulation opportunity or a signal of deeper structural weakness, with technical analysts closely monitoring support levels while tracking aggressive call and put flows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Equity

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

<ul class="summary-bullets"><li>The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.</li><li>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients.</li><li>The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of self-harm among GLP-1 users versus patients taking other diabetes drugs.</li></ul>The U.S. Food and Drug Administration (FDA) on Tuesday asked drugmakers to remove warnings about suicidal thoughts and behavior from the labels of certain popular weight-loss medications after finding no evidence of increased risk.The request applies to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for obesity, including Novo Nordisk’s (NVO) Wegovy and Saxenda, and Eli Lilly’s (LLY) Zepbound.The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.These warnings were originally included as a precaution, based largely on reports tied to older weight-loss drugs rather than GLP-1 therapies specifically. Notably, GLP-1 medications approved for type 2 diabetes have never carried such warnings, and the FDA said the change will ensure consistent labeling across the drug class.<h2 class="st-heading-2">FDA’s Analysis</h2>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients. The analysis found no increased risk of suicidal thoughts, self-injurious behavior (SI/B), or other psychiatric adverse events such as depression or anxiety.The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of intentional self-harm among GLP-1 users compared with patients taking other diabetes drugs.The findings reaffirm results from a preliminary FDA review released in early 2024 and align with conclusions from a separate UK review in the same year. The Medicines and Healthcare products Regulatory Agency (MHRA) had found no evidence linking weight-loss and diabetes drugs to suicides or suicidal thoughts.At the time of writing, <a href="https://stocktwits.com/symbol/LLY">LLY</a> and <a href="https://stocktwits.com/symbol/NVO">NVO</a> stocks were trading 0.1% and 0.2% lower, respectively. Retail sentiment for both stocks was in the ‘bullish’ territory.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-bctx-stock-surge-50-today/cmUX95vR4Ic">Why Did BCTX Stock Surge 90% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings

The request applies to GLP-1 RAs approved for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound.

LLYX
Defiance Daily Target 2X Long LLY ETF

Feed

News

Sentiment

Fundamentals

Info

Latest LLYX News

LLYXDefiance Daily Target 2X Long LLY ETF